Powder: -20°C for 3 years | In solvent: -80°C for 1 year
APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 51.00 | |
5 mg | In stock | $ 122.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 413.00 | |
50 mg | In stock | $ 618.00 | |
100 mg | In stock | $ 879.00 | |
500 mg | In stock | $ 1,790.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 173.00 |
Description | APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury. |
Targets&IC50 | NOX2:0.57 μM (ki), Nox4:0.63 μM (ki), NOX1:ki:1.08 μM |
In vitro | In the mouse podocyte cell line, APX-115 (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
In vivo | APX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[1]. |
Synonyms | Ewha-18278 |
Molecular Weight | 315.8 |
Formula | C17H18ClN3O |
CAS No. | 1395946-75-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (285 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
APX-115 1395946-75-4 Immunology/Inflammation NADPH-oxidase APX115 APX 115 Ewha-18278 inhibitor inhibit